CN100335047C - 阿立哌唑复合制剂和方法 - Google Patents

阿立哌唑复合制剂和方法 Download PDF

Info

Publication number
CN100335047C
CN100335047C CNB038195534A CN03819553A CN100335047C CN 100335047 C CN100335047 C CN 100335047C CN B038195534 A CNB038195534 A CN B038195534A CN 03819553 A CN03819553 A CN 03819553A CN 100335047 C CN100335047 C CN 100335047C
Authority
CN
China
Prior art keywords
aripiprazole
cyclodextrin
formulation
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038195534A
Other languages
English (en)
Chinese (zh)
Other versions
CN1674882A (zh
Inventor
M·内鲁尔卡
V·纳林雷卡
M·多米尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100335047(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1674882A publication Critical patent/CN1674882A/zh
Application granted granted Critical
Publication of CN100335047C publication Critical patent/CN100335047C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB038195534A 2002-08-20 2003-08-14 阿立哌唑复合制剂和方法 Expired - Fee Related CN100335047C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
US60/404,713 2002-08-20

Publications (2)

Publication Number Publication Date
CN1674882A CN1674882A (zh) 2005-09-28
CN100335047C true CN100335047C (zh) 2007-09-05

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038195534A Expired - Fee Related CN100335047C (zh) 2002-08-20 2003-08-14 阿立哌唑复合制剂和方法

Country Status (32)

Country Link
US (8) US7115587B2 (enExample)
EP (1) EP1542668B1 (enExample)
JP (1) JP4729306B2 (enExample)
KR (1) KR101043866B1 (enExample)
CN (1) CN100335047C (enExample)
AR (2) AR040887A1 (enExample)
AT (1) ATE428423T1 (enExample)
AU (1) AU2003269965B2 (enExample)
BR (1) BR0313602A (enExample)
CA (1) CA2495864C (enExample)
CY (1) CY1110331T1 (enExample)
DE (1) DE60327225D1 (enExample)
DK (1) DK1542668T3 (enExample)
ES (1) ES2322953T3 (enExample)
GE (1) GEP20063996B (enExample)
HR (1) HRP20050149B1 (enExample)
IL (1) IL166623A (enExample)
IS (1) IS2878B (enExample)
MX (1) MXPA05001865A (enExample)
MY (1) MY140793A (enExample)
NO (1) NO333458B1 (enExample)
NZ (1) NZ537995A (enExample)
PE (1) PE20040895A1 (enExample)
PL (1) PL212428B1 (enExample)
PT (1) PT1542668E (enExample)
RS (1) RS51903B (enExample)
RU (1) RU2342931C2 (enExample)
SI (1) SI1542668T1 (enExample)
TW (1) TWI307626B (enExample)
UA (1) UA79984C2 (enExample)
WO (1) WO2004017897A2 (enExample)
ZA (1) ZA200501064B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
MXPA06004489A (es) 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
JP5546717B2 (ja) * 2003-12-16 2014-07-09 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾール結晶質形態を調製する方法
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
EP1874272A4 (en) * 2005-04-13 2010-11-10 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS FROM PROSTAGLANDIN DERIVATIVES WITH CONTROLLED RELEASE
CN101232870A (zh) * 2005-06-03 2008-07-30 伊兰制药国际有限公司 纳米微粒甲磺酸伊马替尼制剂
WO2006134877A1 (ja) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited 注射剤
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
PT2170279T (pt) 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
JP5848761B2 (ja) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP3156056B1 (en) 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
GR1008186B (el) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
IL294448A (en) 2013-12-24 2022-09-01 Univ Virginia Commonwealth Uses of oxidized cholesterol sulfates
GR1008442B (el) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
CN105616344A (zh) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 阿立哌唑注射液及其制备方法
HUE059768T2 (hu) * 2016-08-02 2022-12-28 Univ Virginia Commonwealth 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
WO2019102992A1 (ja) * 2017-11-21 2019-05-31 積水化学工業株式会社 皮膚外用剤
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
AU2020395254A1 (en) 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
JP2023551145A (ja) * 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026659A1 (en) * 2001-09-25 2003-04-03 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
WO2003064393A1 (en) * 2002-02-01 2003-08-07 Axon Biochemicals B.V. Thio-carbostyril derivative, its n-oxides and the n-oxides of aripiprazole

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP2893175B2 (ja) * 1988-10-31 1999-05-17 大塚製薬株式会社 カルボスチリル誘導体
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JPH10194996A (ja) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
PL375603A1 (en) 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026659A1 (en) * 2001-09-25 2003-04-03 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
WO2003064393A1 (en) * 2002-02-01 2003-08-07 Axon Biochemicals B.V. Thio-carbostyril derivative, its n-oxides and the n-oxides of aripiprazole

Also Published As

Publication number Publication date
PL374798A1 (en) 2005-10-31
MXPA05001865A (es) 2005-06-03
ZA200501064B (en) 2006-12-27
US20060234979A1 (en) 2006-10-19
US20140235574A1 (en) 2014-08-21
AU2003269965B2 (en) 2008-02-21
CY1110331T1 (el) 2015-01-14
US20150328335A1 (en) 2015-11-19
GEP20063996B (en) 2006-12-11
US20120053145A1 (en) 2012-03-01
ATE428423T1 (de) 2009-05-15
EP1542668B1 (en) 2009-04-15
IS7701A (is) 2005-02-18
BR0313602A (pt) 2005-06-21
CA2495864C (en) 2011-09-27
US20110160224A1 (en) 2011-06-30
DE60327225D1 (de) 2009-05-28
AU2003269965A1 (en) 2004-03-11
IL166623A0 (en) 2006-01-15
IL166623A (en) 2011-07-31
RS51903B (sr) 2012-02-29
NO20050661L (no) 2005-03-16
UA79984C2 (en) 2007-08-10
HRP20050149A2 (en) 2005-10-31
US20130045981A1 (en) 2013-02-21
EP1542668A4 (en) 2007-10-17
US8999952B2 (en) 2015-04-07
US7550445B2 (en) 2009-06-23
KR101043866B1 (ko) 2011-06-22
HRP20050149B1 (hr) 2014-09-12
CN1674882A (zh) 2005-09-28
JP2006501240A (ja) 2006-01-12
IS2878B (is) 2014-04-15
CA2495864A1 (en) 2004-03-04
TWI307626B (en) 2009-03-21
KR20050040927A (ko) 2005-05-03
PL212428B1 (pl) 2012-09-28
MY140793A (en) 2010-01-15
JP4729306B2 (ja) 2011-07-20
DK1542668T3 (da) 2009-07-20
NO333458B1 (no) 2013-06-10
WO2004017897A3 (en) 2004-12-02
US20040077594A1 (en) 2004-04-22
PE20040895A1 (es) 2004-11-20
EP1542668A2 (en) 2005-06-22
PT1542668E (pt) 2009-06-09
AR040887A1 (es) 2005-04-20
WO2004017897A2 (en) 2004-03-04
RS20050118A (sr) 2007-06-04
RU2005107471A (ru) 2005-09-10
US7115587B2 (en) 2006-10-03
SI1542668T1 (sl) 2009-08-31
TW200405813A (en) 2004-04-16
US20090186903A1 (en) 2009-07-23
AR102101A2 (es) 2017-02-01
NZ537995A (en) 2007-11-30
RU2342931C2 (ru) 2009-01-10
ES2322953T3 (es) 2009-07-02

Similar Documents

Publication Publication Date Title
CN100335047C (zh) 阿立哌唑复合制剂和方法
RU2310450C2 (ru) Новые депо-препараты для инъекций
JP6246715B2 (ja) ブレクスピプラゾール及び置換β−シクロデキストリンを含む薬学的製剤
US20040146562A1 (en) Depot formulations in the form of a suspension
TWI738100B (zh) Bcl-2抑制劑之基於環糊精之調配物
TW200800270A (en) Factor Xa inhibitor formulation and method
CN101340933A (zh) 具有环糊精的因子xa抑制剂包合配合物
JP2005520856A (ja) 貯蔵時に安定なエプレレノン製剤
OA20228A (en) Cyclodextrin-based formulation of A BCL2 inhibitor.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB CO.

Effective date: 20141009

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20141009

Address after: Tokyo, Japan, Japan

Patentee after: Otsuka Pharmaceutical Co., Ltd.

Address before: new jersey

Patentee before: Bristol-Myers Squibb Co.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070905

Termination date: 20190814